Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
11.80
-0.74 (-5.90%)
At close: Sep 24, 2026, 4:00 PM EDT
11.70
-0.10 (-0.85%)
After-hours: Sep 24, 2026, 7:59 PM EDT
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 37 employees as of December 31, 2025. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$1,462,946
Market Cap
992.63M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 37 | 6 | 19.35% | 37 | 0 |
| Dec 31, 2024 | 31 | 3 | 10.71% | 31 | 0 |
| Dec 31, 2023 | 28 | -1 | -3.45% | 28 | 0 |
| Dec 31, 2022 | 29 | 1 | 3.57% | 29 | 0 |
| Dec 31, 2021 | 28 | -14 | -33.33% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Kura Oncology | 260 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Janux Therapeutics | 113 |
| Adlai Nortye Group | 109 |
| Odyssey Therapeutics | 100 |
| Alto Neuroscience | 68 |
CRVS News
- 14 days ago - Corvus Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 21 days ago - Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - Corvus Pharmaceuticals Earnings release: Q2 2026 - Filings
- 7 weeks ago - Corvus Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Corvus Pharmaceuticals reports Q2 EPS (19c), consensus (17c) - TheFly
- 7 weeks ago - Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire